Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

EP: 1.Understanding Cancer Changes and Testing: How Testing Guides Your Metastatic Breast Cancer Treatment

EP: 2.Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options

EP: 3.Exploring a Patient Case: Biomarker Testing After Progression and Discussing Treatment Choices With Your Care Team

EP: 4.EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success

EP: 5.Managing Elacestrant Treatment: From Patient Selection to Supportive Care

Now Viewing

EP: 6.Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

EP: 7.Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer

Video content above is prompted by the following:

Clinical Brief: Real-World Evidence Supporting Elacestrant Use

Main Discussion Topics:

• Real-world outcomes exceeding clinical trial results (unusual finding)
• GUARDIAN database analysis: 6.4 months median time to treatment failure
• Komoda database: 6.8 months progression-free survival (9.4 months if fulvestrant-naive)
• Expert clinical experience aligning with real-world data
• Importance of appropriate patient selection for optimal outcomes

Key Points for Physicians:

• Real-world PFS (6.4-6.8 months) exceeds EMERALD trial results (3.8 months)
• Fulvestrant-naive patients show particularly strong outcomes (9.4 months)
• Early adopters report better results with refined patient selection
• Confirms benefit of using elacestrant in second-line for appropriate patients
• Real-world data validates subgroup findings from EMERALD

The real-world evidence conclusively demonstrates that proper patient selection based on EMERALD subgroup analyses results in significantly improved clinical outcomes compared with the overall trial population.